This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2008 Sep 1;26(25):4217-9.

doi: 10.1200/JCO.2008.18.7286.

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

Salvatore Artale, Andrea Sartore-Bianchi, Silvio Marco Veronese, Valentina Gambi, Carolina Silvia Sarnataro, Marcello Gambacorta, Calogero Lauricella, Salvatore Siena

PMID: 18757341
DOI: 10.1200/JCO.2008.18.7286

Free article

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

Salvatore Artale et al. J Clin Oncol. 2008.

Free article

. 2008 Sep 1;26(25):4217-9.

doi: 10.1200/JCO.2008.18.7286.

Authors

Salvatore Artale, Andrea Sartore-Bianchi, Silvio Marco Veronese, Valentina Gambi, Carolina Silvia Sarnataro, Marcello Gambacorta, Calogero Lauricella, Salvatore Siena

PMID: 18757341
DOI: 10.1200/JCO.2008.18.7286

No abstract available

PubMed Disclaimer

Comment in

KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases.
Velho S, Oliveira C, Seruca R. Velho S, et al. J Clin Oncol. 2009 Jan 1;27(1):158-9; author reply 159. doi: 10.1200/JCO.2008.20.1525. Epub 2008 Dec 1. J Clin Oncol. 2009. PMID: 19047277 No abstract available.

Similar articles

Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Baldus SE, et al. Clin Cancer Res. 2010 Feb 1;16(3):790-9. doi: 10.1158/1078-0432.CCR-09-2446. Epub 2010 Jan 26. Clin Cancer Res. 2010. PMID: 20103678
Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation.
Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, Kimura K, Kambara T, MacPhee DG, Young J, Leggett BA, Jass JR, Tanaka N, Matsubara N. Nagasaka T, et al. J Clin Oncol. 2004 Nov 15;22(22):4584-94. doi: 10.1200/JCO.2004.02.154. J Clin Oncol. 2004. PMID: 15542810
Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression.
Calistri D, Rengucci C, Seymour I, Lattuneddu A, Polifemo AM, Monti F, Saragoni L, Amadori D. Calistri D, et al. J Cell Physiol. 2005 Aug;204(2):484-8. doi: 10.1002/jcp.20310. J Cell Physiol. 2005. PMID: 15702478
Axillary Lymph Node Involvement, a Unique Pattern of Metastasis in BRAF-Mutant Colorectal Cancer.
Lipsyc MD, Yaeger R, Dengel LT, Saltz L. Lipsyc MD, et al. JAMA Oncol. 2015 Aug;1(5):686-7. doi: 10.1001/jamaoncol.2015.0569. JAMA Oncol. 2015. PMID: 26182332 Free PMC article. Review. No abstract available.
Prevalence of BRAF gene mutation in samples of primary and metastatic colorectal cancer: A meta-analysis.
Moosazadeh M, Sadough A, Afshari M, Barzegari S, Janbabaee G, Tabrizi R, Akbari M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Rostami-Maskopaee F. Moosazadeh M, et al. Eur J Cancer Care (Engl). 2019 Nov;28(6):e13160. doi: 10.1111/ecc.13160. Epub 2019 Sep 3. Eur J Cancer Care (Engl). 2019. PMID: 31482595

See all similar articles

Cited by

KRAS mutation and NF-κB activation indicates tolerance of chemotherapy and poor prognosis in colorectal cancer.
Lin G, Zheng XW, Li C, Chen Q, Ye YB. Lin G, et al. Dig Dis Sci. 2012 Sep;57(9):2325-33. doi: 10.1007/s10620-012-2172-x. Epub 2012 Apr 24. Dig Dis Sci. 2012. PMID: 22526587
KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis.
Cejas P, López-Gómez M, Aguayo C, Madero R, de Castro Carpeño J, Belda-Iniesta C, Barriuso J, Moreno García V, Larrauri J, López R, Casado E, Gonzalez-Barón M, Feliu J. Cejas P, et al. PLoS One. 2009 Dec 18;4(12):e8199. doi: 10.1371/journal.pone.0008199. PLoS One. 2009. PMID: 20020061 Free PMC article.
Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer.
Ličar A, Cerkovnik P, Novaković S. Ličar A, et al. Med Oncol. 2011 Dec;28(4):1048-53. doi: 10.1007/s12032-010-9631-z. Epub 2010 Jul 20. Med Oncol. 2011. PMID: 20645028
The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer.
Fanelli GN, Dal Pozzo CA, Depetris I, Schirripa M, Brignola S, Biason P, Balistreri M, Dal Santo L, Lonardi S, Munari G, Loupakis F, Fassan M. Fanelli GN, et al. Cancer Cell Int. 2020 Jan 29;20:30. doi: 10.1186/s12935-020-1117-2. eCollection 2020. Cancer Cell Int. 2020. PMID: 32015690 Free PMC article. Review.
Prediction of KRAS, NRAS and BRAF status in colorectal cancer patients with liver metastasis using a deep artificial neural network based on radiomics and semantic features.
Shi R, Chen W, Yang B, Qu J, Cheng Y, Zhu Z, Gao Y, Wang Q, Liu Y, Li Z, Qu X. Shi R, et al. Am J Cancer Res. 2020 Dec 1;10(12):4513-4526. eCollection 2020. Am J Cancer Res. 2020. PMID: 33415015 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal